Taysha Gene Therapies Inc (NASDAQ: TSHA) is 30.51% higher on its value in year-to-date trading and has touched a low of $1.27 and a high of $4.32 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TSHA stock was last observed hovering at around $2.28 in the last trading session, with the day’s gains setting it 0.03%.
Currently trading at $2.31, the stock is 5.75% and -12.43% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.49 million and changing 1.32% at the moment leaves the stock 0.08% off its SMA200. TSHA registered 8.45% gain for a year compared to 6-month gain of 58.22%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -6.10% loss in the last 1 month and extending the period to 3 months gives it a -10.12%, and is 13.79% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.29% over the week and 7.63% over the month.
Taysha Gene Therapies Inc (TSHA) has around 52 employees, a market worth around $473.41M and $12.87M in sales. Profit margin for the company is -888.18%. Distance from 52-week low is 81.89% and -46.53% from its 52-week high. The company has generated returns on investments over the last 12 months (-69.36%).
The EPS is expected to grow by 61.72% this year
The shares outstanding are 186.96M, and float is at 157.66M with Short Float at 14.72%.
Taysha Gene Therapies Inc (TSHA) Insider Activity
The most recent transaction is an insider purchase by Manning Paul B, the company’s 10% Owner. SEC filings show that Manning Paul B bought 1,333,333 shares of the company’s common stock on Jun 27 ’24 at a price of $2.25 per share for a total of $3.0 million. Following the purchase, the insider now owns 1.33 million shares.
Taysha Gene Therapies Inc disclosed in a document filed with the SEC on Nov 17 ’23 that Manning Paul B (10% Owner) bought a total of 100,000 shares of the company’s common stock. The trade occurred on Nov 17 ’23 and was made at $1.63 per share for $0.16 million. Following the transaction, the insider now directly holds 16.57 million shares of the TSHA stock.
Still, SEC filings show that on Aug 24 ’23, Alam Kamran (Chief Financial Officer) disposed off 33,000 shares at an average price of $2.33 for $76890.0. The insider now directly holds 258,042 shares of Taysha Gene Therapies Inc (TSHA).
